A recent study showed that TKIs could enrich cancer stem cells and induce epithelial–mesenchymal transitions, subsequently resulting in drug resistance, and these properties are associated with aberrant activation of the AKT/FOXM1/STMN1 axis [14]. The gene discussed is AKT1; the disease is cancer.